Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.
Expert Rev Vaccines
; 14(1): 9-20, 2015 Jan.
Article
en En
| MEDLINE
| ID: mdl-25420897
ABSTRACT
Racotumomab-alum vaccine is an anti-idiotypic vaccine able to mimic the tumor-associated antigen NeuGcGM3. Different Phase I clinical trials and compassionate use studies demonstrated its low toxicity and capacity to induce a strong anti-NeuGcGM3 response, able to bind and directly kill tumor cells expressing the antigen. A Phase II/III randomized double-blind clinical trial in advanced non-small cell lung cancer patients showed a significant improvement in overall survival and progression-free survival for racotumomab-alum versus placebo. Patients who developed anti-NeuGcGM3 antibodies capable of binding and killing NeuGcGM3 expressing tumor cells showed significantly longer median survival times. The impact of using racotumomab-alum as switch maintenance followed by second-line therapy is currently being explored in a new randomized, multinational Phase III study.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Adyuvantes Inmunológicos
/
Carcinoma de Pulmón de Células no Pequeñas
/
Vacunas contra el Cáncer
/
Compuestos de Alumbre
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Expert Rev Vaccines
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2015
Tipo del documento:
Article
País de afiliación:
Cuba